
Quarterly ResultJul 30, 2026, 04:09 PM
Cerus Q2 Product Revenue +10% to $57.4M; Raises FY26 Guidance
AI Summary
Cerus Corporation announced its second quarter 2026 financial results, reporting total revenue of $63.3 million and product revenue of $57.4 million, representing 5% and 10% year-over-year growth, respectively. The company raised the lower end of its full-year 2026 product revenue guidance to a range of $229 million to $231 million and increased its IFC sales outlook to $23 million to $25 million. Key business updates include the submission of a PMA for the INTERCEPT Blood System for Platelets with INT200 Illuminator to the FDA, completion of debt refinancing, and an expansion of its BARDA collaboration for the INTERCEPT Red Blood Cell system.
Key Highlights
- Q2 2026 total revenue was $63.3 million, up 5% year-over-year.
- Q2 2026 product revenue reached $57.4 million, a 10% increase year-over-year.
- Full-year 2026 product revenue guidance raised to $229 million to $231 million.
- 2026 IFC sales outlook increased to $23 million to $25 million, up 40% to 50% year-over-year.
- IFC demand volumes grew approximately 20% in Q2 2026 compared to prior year.
- Submitted PMA for INTERCEPT Blood System for Platelets with INT200 Illuminator to FDA.
- Completed debt refinancing, reducing term loan by $30 million.
- Expanded BARDA collaboration by $21.9 million to $270.5 million for Red Blood Cell system development.
- Cash, cash equivalents, and short-term investments totaled $56.3 million at June 30, 2026.
- Net loss attributable to Cerus Corporation was $2.9 million in Q2 2026, an improvement from $5.7 million loss in Q2 2025.
- Non-GAAP adjusted EBITDA was positive $3.0 million in Q2 2026, up from $0.9 million in Q2 2025.
Price Impact
More from CERS